



Patent Docket P2026R1

# THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Liu et al.

Serial No.: 10/813,483

Filed: March 29, 2004

For:

HIGH CONCENTRATION ANTIBODY

AND PROTEIN FORMULATIONS

Group Art Unit: 1644

Examiner: Yunsoo Kim

Confirmation No: 5594

CUSTOMER NO: 09157

EXPRESS MAIL EL 872102831 US June 23, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

# [] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

#### [X] 37 CFR §1.97(c)

 by the applicants after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

## [] 37 CFR §1.97(d)

• after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [X] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

The patent which is marked with an asterisk (\*) in the attached PTO-1449 form is not supplied because this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international patent applications that have entered the national stage under 35 U.S.C. §371 after June 30, 2003 (1276 OG 55). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

Serial No.: 10/813,483

Date: June 23, 2005

[]	given	for	each	listed	item
LJ	<b>6</b>				

[] given for only non-English language listed item(s) [Required]

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489

<b>JIPTO</b>	-1449	07 2005 W	U.S.	Dept. of Commerce	Atty Docket No.	I .	rial No.		
	NO	<u>[</u> ]	Patent	and Trademark Office	P2026R1	10/	/813,483		
ר טוב ח	ieci velibre Cara t	OV ADDISTANT			Applicant	Liu et al.			
	_								
Jse se	veral sheets if necessan	y) <sup>.</sup> 					Group 1644		
			U.S. PAT	ENT DOCUMENTS					
	Document Number	Date		Name	Class	Subclass	Filing Date		
*25	6,541,606	01.04.03	Margolin et a	11.					
			FOREIGN	PATENT DOCUMENTS	S		<u></u>		
	Document Number	Date		Country	Class	Subclass	Translation Yes No		
26	2002/072636	19.09.02	WO	-			1		
	<u></u>	OTHER DISCI	LOSURES (Includi	na Author, Title, Date,	Pertinent Pages, e	<u></u> tc.)	<u> </u>		
27		, "Rational Des	sign of Stable		• •	•	ical Advice"		
28	Presented by The Stability Confere	University of ence", Breckenr	Colorado Cente:	r for Pharmaceutic (July 17-19, 2003	al Biotechnolog	y, "2003 Co.	lorado Protein		
	·			·					
					·				
							٠.		
<u> </u>									
:	,		<u>:</u>						
r .				Dat	te Considered				
er: Init	ial if reference consider	red, whether or no	ot citation is in cor	Iformance with MPEP 6	309; draw line throug	gh citation	. •		
	26 27 28 er: Init	Document Number  *25 6,541,606  Document Number  26 2002/072636  Carpenter et al., Pharmaceutical Re  Stability Confere	OF DISCLOSURES CITED BY APPLICANT  Jes several sheets if necessary)  Document Number  Date  *25 6,541,606 01.04.03  Document Number Date  26 2002/072636 19.09.02  OTHER DISCL  Carpenter et al., "Rational Des Pharmaceutical Research 14(8):9  Presented by The University of Stability Conference", Breckenr  Stability Conference", Breckenr	OF DISCLOSURES CITE BY APPRICANT  Joe several sheets if necessary)  U.S. PATI  Document Number Date  *25 6,541,606 01.04.03 Margolin et a  FOREIGN  Document Number Date  26 2002/072636 19.09.02 WO  OTHER DISCLOSURES (Includiant)  27 Pharmaceutical Research 14 (8):969-975 (1997)  Presented by The University of Colorado Center Stability Conference", Breckenridge, Colorado  Stability Conference", Breckenridge, Colorado  et al., "Rational Design of Stable 1"  Presented by The University of Colorado Center Stability Conference", Breckenridge, Colorado  10 Presented by The University of Colorado Center Stability Conference", Breckenridge, Colorado  28 Stability Conference Breckenridge, Colorado  29 Presented by The University of Colorado Center Stability Conference Breckenridge, Colorado	OF DISCLOSURES CREATED PARENTEANT  Jose several sheets if necessary)  U.S. PATENT DOCUMENTS    Document Number   Date   Name	Openment Number Date Name Class    Considered   Document Number   Date   Name   Class	Patent and trademant Office  Applicant Liu et al. Filing Date 29 Max 2004 164  U.S. PATENT DOCUMENTS  U.S. PATENT DOCUMENTS  Document Number Date Name Class Subclass  FOREIGN PATENT DOCUMENTS  Document Number Date Country Class Subclass  FOREIGN PATENT DOCUMENTS  Document Number Date Country Class Subclass  OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)  Carpenter et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Pract: Pharmaceutical Research 14(8):959-975 (1997)  Presented by The University of Colorado Center for Pharmaceutical Biotechnology, "2003 Col Stablility Conference", Brockenridge, Colorado (July 17-19, 2003)  Date Considered  Date Considered  Et. Initial if reference considered, whether or not citation is in conformance with MPEP 600 draw line through citation of the process		